BioAge Labs, Inc.
BIOAHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeBioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. With a market capitalization of $234.1M, it sits in micro-cap territory. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Market Cap
$234.1M
Beta
1.08
P/E (TTM)
—
P/E (Fwd)
-2.04
EPS (TTM)
$-2.39
EPS (Fwd)
$-2.50
ROE
-28.2%
ROA
-18.5%
Cash
$318.7M
Total Debt
$2.8M
Free CF
-$58.1M
52W Change
-33.2%
Annual Financials
Cash vs Debt
Where BIOA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BIOA finished 67.19% below its 150-day moving average ($15.21) and 69.37% below its 200-day moving average ($16.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BIOA overbought or oversold?
At the October 20, 2026 close, BIOA's RSI(14) was 10.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $318.7M in cash comfortably exceeding the $2.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$58.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -28.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, BIOA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BioAge Labs, Inc.'s trajectory.